drugset / Trial / NCT05201469

VIBRANT: VIB4920 for Active Lupus Nephritis

NCT05201469

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

Timeline

Start
2022-05-16
Primary completion
2026-08
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dazodalibep Protein / enzyme biologic 1500 mg Intravenous

Indications